Eli Lilly’s Guidance ‘Packs On the Pounds’ as Zepbound and Mounjaro Send Shares Soaring

“Whole lotta Zep…” - Robert Plant Eli Lilly 

Eli Lilly did it again (read: pistol-whipped Novo). Thanks to America’s obesity problem, Lilly posted a yuge beat on the top and bottom lines Thursday, with adjusted EPS of $7.48 vs. $6.26 expected on $24.4B in revenue vs. $22.61B. It also raised its full-year sales outlook for the third time this year, and shares were up about 4% premarket.

Novo’s little bro now expects 2026 revenue of $91B to $92B, up from $85B to $87B, which, excuse me, how much? Fun fact: Back in February, it was guiding to $80B to $83B. Granted, about $900M of this quarter came from one-time goodies, like a $410M Jardiance milestone payment from Boehringer Ingelheim. 

Mounjaro simply does not miss. Sales of the world’s top-selling drug jumped 65% to $10.72B (vs. $10.10B expected), and nearly doubled outside the US (think: +93%). Zepbound chipped in $5.35B, up 49% and ahead of the $5.09B the Street wanted.

That’s after Donny Politics (read: POTUS) had his way with GLP-1 makers on pricing last year. US revenue still climbed 34% to $15.1B, because a 41% jump in volume (Happy Halloween, Hershey) more than covered a 7% drop in prices. Medicare also started covering GLP-1s for weight loss in July. 

Oh, and because Lilly continues to dance on Novo’s grave, it also held 63% of the US obesity and diabetes drug market in Q3, vs. 36.6% for the European Weight Watchers. Internationally, it’s 58.4% vs. 41.6%. 

So naturally, Novo went crying to a judge over the cruelty of the free market (again). It sued Lilly in July over its Zepbound and Mounjaro ads, and on Monday, a federal judge refused to block them, noting that “Novo engaged in a nearly identical advertising strategy.” #getrekt. It’s just that Foundayo, the once-daily Flintstone Vitamin obesity pill that launched in April, brought in $184M vs. ~$229M expected, its second miss in two quarters on the market. Woof. Novo’s Wegovy pill, which beat it to market in January, did roughly $494M last quarter.

Of course, Chief Shopping Officer (read: CEO) Dave Ricks has been snapping up biotechs all year, and the deals Lilly booked this quarter came with $4.57 a share in charges (read: paying up for drugs that don’t exist yet). That more than wiped out a $4.07 raise to the underlying profit outlook, so adjusted EPS guidance actually slipped to $35 to $36, from $35.50 to $36.50. Treat yo self.

TLDR: The trillion-dollar Weight Watchers executioner can get America to take a needle in the thigh every week… it just can’t get anyone to swallow. Place your bets accordingly, friends…

Until next time! 

At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.